Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

CLSN: OVATION 2 Study 85% Enrolled…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Benzinga

EXCLUSIVE: Benzinga's 2022 Esports Listmakers Are Driving Gaming Forward

Financial media and data company Benzinga is capitalizing on its mission to bridge the gap between retail and institutional investors by holding free virtual events featuring speakers from innovative companies.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Pharmaceuticals Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

Benzinga

This Is What Whales Are Betting On Lucid Gr

A whale with a lot of money to spend has taken a noticeably bullish stance on Lucid Gr. Looking at options history for Lucid Gr (NASDAQ:LCID) we detected 27 strange trades.

Benzinga

Check Out What Whales Are Doing With MELI

A whale with a lot of money to spend has taken a noticeably bearish stance on MercadoLibre. Looking at options history for MercadoLibre (NASDAQ:MELI) we detected 36 strange trades.

Benzinga

Pinduoduo Whale Trades For June 17

Someone with a lot of money to spend has taken a bullish stance on Pinduoduo (NASDAQ:PDD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gores Guggenheim Soars As Polestar Merger Approaches: Here's How The EV SPAC Looks

Gores Guggenheim Inc (NASDAQ: GGPI) was soaring up more than 13% on Friday, heavily outpacing the general market, which saw the S&P 500 trading up about 0.7%.

Benzinga

Cannabis Movers & Shakers: 22nd Century Group, Houseplant, Proven Media

22nd Century Group Names New CFO 22nd Century Group (NASDAQ: XXII) has appointed f R. Hugh Kinsman to oversee its financial department. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.

Benzinga

Vita Coco CFO Kevin Benmoussa Steps Down

Vita Coco Company Inc (NASDAQ:COCO) said its Chief Financial Officer Kevin Benmoussa would depart the company later in 2022. Kevin is likely to pursue an expanded finance and executive role outside of the beverage industry. However, he will remain at The Vita Coco Company until August 31 to complete the second-quarter reporting activity. The…

Benzinga

Elon Musk Just Exercised Stock Options In This Company — And No It Wasn't Tesla

The world’s richest person owns stakes in Tesla Inc (NASDAQ: TSLA), SpaceX, Twitter Inc (NYSE: TWTR) and several other companies.

Benzinga

Dow Jumps Over 100 Points; Crude Oil Down 7%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Friday.

Benzinga

Rivian Automotive Plans To Construct Wind Turbine At Illinois Campus

Rivian Automotive Inc (NASDAQ:RIVN) plans to establish a large-scale wind turbine at its Normal manufacturing campus in Illinois. The automaker expects to generate clean energy to enable new R1 vehicles to be powered by renewables for their first charge. Rivian installed a 783-kilowatt solar canopy in early 2022, which is scheduled to begin…

Benzinga

Lucid Group Opens Retail Studio In Colorado

Electric car maker Lucid Group Inc (NASDAQ:LCID) has opened its first studio location in Denver, Colorado, at the Cherry Creek Shopping Center. The studio marks twenty-seven studios and service center locations open in North America. The Lucid Studio in Cherry Creek will be open to the public on June 18. "The state of…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

Benzinga

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

Benzinga

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors. BMO writes that Graphite's platform is expected to be safer than existing…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Legend Biotech Shares Move Higher After Bullish BMO Pitch

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due…

Benzinga

10 Information Technology Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Benzinga

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Benzinga

Here's How Much $1000 Invested In Verisk Analytics 10 Years Ago Would Be Worth Today

Verisk Analytics (NASDAQ:VRSK) has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 12.86%. Currently, Verisk Analytics has a market capitalization of $25.64 billion.

Benzinga

As Bears Grip Tesla Stock, Here's Where To Watch For The Bounce

Tesla Inc (NASDAQ: TSLA) was trading about 2% higher on Friday, rebounding slightly from a bearish day on Thursday, which saw the stock slide about 4% in tandem with the general markets.

Benzinga

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

Benzinga

More Game Of Thrones Content Is Coming With A Jon Snow Series: What Investors Should Know

The "Game of Thrones" franchise will live on with a highly anticipated sequel series — just the latest in a string of spinoff programming inspired by the popular HBO show that spanned eight seasons.

1 … 422 423 424 425

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Warner Bros Discovery

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.